From treating breast to pancreatic, to colorectal, and beyond, Mobetron continues to be the leading IORT technology in China with it first installation in the Jiangsu Province
SUNNYVALE, Calif., — IntraOp Medical Corporation today announced its ninth installation in China, the world’s most populated country and second largest economy. IntraOp®, the developer and manufacturer of the Mobetron®, an electron based intraoperative radiation therapy (IORT) device, has been providing life-saving cancer treatment technology to leading healthcare institutions worldwide for more than 20 years.
Nanjing General Hospital (NGH) has officially become the ninth hospital in China to install the Mobetron and the first in Jiangsu Province. NGH joins other leadingChina institutions such as 301 Beijing General Hospital, Chinese Academy of Medical Science (CAMS) and Shanghai Tumor Hospital in bringing IntraOp’s innovative Mobetron to cancer patients in China.
Dr. Zhu Xixu, Director of the Department of Radiation Oncology at NGH. “Electron IORT has demonstrated significant benefits in the treatment of locally advanced and recurrent cancers as well early stage breast cancer.
“We are delighted to be the first hospital in Jiangsuprovince to install a Mobetron and make this advanced technology available to patients in the region,” said Dr. Zhu Xixu, Director of the Department of Radiation Oncology at NGH. “Electron IORT has demonstrated significant benefits in the treatment of locally advanced and recurrent cancers as well early stage breast cancer. The Mobetron expands our ability to treat these cancers and ensures our patients have access to the best possible treatment options to aid their fight against cancer.”
“For more than a decade, Mobetron has been the leading IORT technology in China and we are honored to be adding NGH to our network of hospitals there. Expanding the availability of electron IORT to Chinese physicians and their patients suffering a variety of cancers is a top priority for IntraOp,” said IntraOp CEOBruce Khouri. “We are committed to advancing the standard of care for cancer treatment with the Mobetron, the world’s only self-shielded, portable LINAC device designed to deliver precise, targeted doses of cancer killing radiation during surgery,” Khouri added.